(NASDAQ: JANX) Janux Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.21%.
Janux Therapeutics's earnings in 2026 is -$114,478,000.On average, 21 Wall Street analysts forecast JANX's earnings for 2026 to be -$119,614,712, with the lowest JANX earnings forecast at -$178,098,707, and the highest JANX earnings forecast at -$66,594,915. On average, 18 Wall Street analysts forecast JANX's earnings for 2027 to be -$171,433,118, with the lowest JANX earnings forecast at -$209,176,334, and the highest JANX earnings forecast at -$123,584,793.
In 2028, JANX is forecast to generate -$209,761,784 in earnings, with the lowest earnings forecast at -$304,202,155 and the highest earnings forecast at -$131,268,822.